EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increased Exacerbation Reduction Over Time with Tezepelumab in Severe Asthma: CROSSROADS-4

Jessica K DeMartino, Christopher S Ambrose, Cheryl Xiang, Fan Mu, Yipeng Gao, Allister Ho, Jingyi Chen, David A Queen, Santiago Zuluaga Sanchez, Weily Soong, Laren Tan

The Journal of Allergy and Clinical Immunology: In Practice · 2026-10

DOI: 10.1016/j.jaip.2026.10.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-10. Verfasst von Jessica K DeMartino und 10 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Wilmington, DE, USA. Electronic address: jessica.demartino@astrazeneca.com. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca PLC, Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tezepelumab is a monoclonal antibody approved in the United States for severe asthma. Real-world evidence of effectiveness remains limited. OBJECTIVE: To evaluate the effectiveness of tezepelumab in reducing annualized asthma exacerbation rates (AAERs) and healthcare resource utilization (HRU) in the United States. METHODS: This retrospective, self-controlled, pre-post cohort study used data from Symphony Health, an ICON plc Company, PatientSource®, December 1, 2020, to June 30, 2024. Eligible patients were ≥12 years, had ≥2 records of tezepelumab, and experienced ≥2 asthma exacerbations in the 12 months before tezepelumab initiation, with index date being the day after initiation. AAERs and asthma exacerbation-related HRU were compared between the 12 months pre- and post-index. AAERs were also evaluated across patient subgroups. RESULTS: A total of 527 patients were included. AAERs decreased significantly from 2.81 to 1.26 per person-year (55% decrease; 95% confidence interval [CI] [51%, 59%]; p

Schlagwörter

Stichwörter der Autor:innen

Tezepelumabasthmaexacerbationhealthcare resource utilizationreal-world study

Autor:innen und Institutionen

  • AstraZeneca, Wilmington, DE, USA. Electronic address: jessica.demartino@astrazeneca.com.
  • AstraZeneca, Wilmington, DE, USA.
  • Analysis Group, Boston, MA, USA.
  • Amgen, Uxbridge, UK.
  • AllerVie Health - Alabama Allergy & Asthma Center, Birmingham, AL, USA.
  • Loma Linda University Health, Loma Linda, CA, USA.

Förderung

  • AstraZeneca PLC
  • Amgen Inc

Zitieren

APA

DeMartino, J. K., Ambrose, C. S., Xiang, C., Mu, F., Gao, Y., Ho, A., Chen, J., Queen, D. A., Sanchez, S. Z., Soong, W., & Tan, L. (2026). Increased Exacerbation Reduction Over Time with Tezepelumab in Severe Asthma: CROSSROADS-4. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2026.10.024

Vancouver

DeMartino JK, Ambrose CS, Xiang C, Mu F, Gao Y, Ho A, et al. Increased Exacerbation Reduction Over Time with Tezepelumab in Severe Asthma: CROSSROADS-4. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2026.10.024

BibTeX
@article{DeMartino2026,
  author = {DeMartino, Jessica K and Ambrose, Christopher S and Xiang, Cheryl and Mu, Fan and Gao, Yipeng and Ho, Allister and Chen, Jingyi and Queen, David A and Sanchez, Santiago Zuluaga and Soong, Weily and Tan, Laren},
  title = {Increased Exacerbation Reduction Over Time with Tezepelumab in Severe Asthma: CROSSROADS-4},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  doi = {10.1016/j.jaip.2026.10.024}
}
Kostenlos starten →